It would have been interesting to have sat in on the senior management meetings at Merck that thrashed out the Organon ...

Organon (NYSE:OGN) announced Tuesday the acquisition of regulatory and commercial rights linked to Tofidence, a biosimilar developed by Biogen (NASDAQ:BIIB) as an intravenous therapy targeting ...

Organon has announced the acquisition of the US regulatory and commercial rights for intravenous infusion of the Actemra biosimilar, Tofidence, from Biogen. The move is set to bolster and widen ...

Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - CEOMatt Walsh ...

JERSEY CITY, N.J., April 01, 2025--Organon announced it has acquired regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion. JERSEY CITY ...

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) a global healthcare company with a focus on women’s health, today announced the appointment of Ramona A. Sequeira, President of the Global ...

Thank you for joining Organon's first quarter earnings call ... Renflexis and Hadlima are mainly supplied from Korea and the EU. For recently acquired Tofidence, that product is manufactured in China, ...